Dietary Anthocyanins Improve Lipid Metabolism in a Dose - Dependent Manner
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 169 participants.
Also called NCT03415503
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose prevention
- Phase
- Phase 3
- Enrolled
- 169 participants
- Sponsor
- Registry
-
NCT03415503
-
- Other papers using this trial's data
- Dose-dependent reductions in plasma ceramides after anthocyanin supplementation are associated with improvements in plasma lipids and cholesterol efflux capacity in dyslipidemia: A randomized controlled trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT03415503. Randomized; double masking; primary purpose prevention. Start 2018-10-01 (actual); primary completion 2019-10-01 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Dietary Anthocyanins Improve Lipid Metabolism in a Dose - Dependent Manner
- Condition
- Dyslipidemias
- Intervention (Drug)
- Medox® Anthocyanin capsules
- Lead sponsor
- Sun Yat-sen University
Record details
- Record id
cardio:ct-nct03415503- Content hash
4b4dc036f2620015964bc50fa8010e41c54f31fb3115e603de21d70baa68b9b8